Judge: FDA Ignored Evidence in ‘Deeming’ Premium Cigars

Events by tobaccoreporter
Jul.07.2022

The U.S. Food and Drug Administration ignored evidence about health risks in considering premium cigars to be subject to same law as cigarettes, a federal judge ruled on July 5, reports Reuters.  

Judge: FDA Ignored Evidence in ‘Deeming’ Premium Cigars

The litigation focuses on the 2016 Deeming Rule, in which the agency identified a wide range of tobacco products, including premium cigars, to be subject to its regulatory authority along with cigarettes under the Family Smoking Prevention and Tobacco Control Act.

 

The FDA rule requires cigar makers to register their products annually, provide ingredient lists for each product and submit products for laboratory testing—procedures the premium cigar industry considers impractical for its handmade, “artisan” products.

 

The Premium Cigar Association and Cigar Rights of America challenged the Deeming Rule, arguing that, unlike cigarettes and e-cigarettes, premium cigars do not appeal to young people and are not associated with addiction. They cited studies showing that young people are unlikely to use premium cigars, that users of premium cigars are unlikely to smoke them frequently and that infrequent cigar use is not associated with increased mortality.

 

U.S. District Judge Amit Mehta in Washington DC agreed that the FDA had not adequately considered the studies cited by the plaintiffs, instead asserting that there was “no evidence” that premium cigars were less harmful.

 

“Where, as here, an agency speaks in absolute terms that there is no evidence, it acts arbitrarily and capriciously when there is in fact pertinent record evidence and the agency ignores or overlooks it,” the judge wrote.

 

Judge Mehta asked the FDA and the industry groups to submit briefs on whether he should vacate the FDA’s decision or simply remand the matter back to the agency.

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

KT&G Q3 Net Profit Up 73%; Overseas NGP Revenue Nearly Doubles, Nicotine Pouch Expansion Set to Launch Globally
KT&G Q3 Net Profit Up 73%; Overseas NGP Revenue Nearly Doubles, Nicotine Pouch Expansion Set to Launch Globally
KT&G reported its Q3 2025 financial results, posting revenue of KRW 1.83 trillion (≈USD 1.31 billion) and a 73.4% year-over-year surge in net profit—marking the company’s highest operating profit in five years. The Next Generation Product (NGP) segment performed strongly, generating KRW 279.1 billion (≈USD 199 million) in revenue, with overseas NGP sales more than doubling year-over-year.
Nov.06
Company | BAT: glo Hilo Series to Expand to Italy, Poland and Serbia
Company | BAT: glo Hilo Series to Expand to Italy, Poland and Serbia
Recently, British American Tobacco (BAT) announced on social media that it has officially launched the glo™ Hilo product line nationwide in Japan, including the new glo™ Hilo, glo™ Hilo Plus, and virto™ heated sticks. BAT said the series will soon expand to Italy, Poland, and Serbia. The company aims to reach 50 million adult consumers of smokeless products by 2030 and to become a predominantly smokeless business by 2035.
Sep.12 by 2FIRSTS.ai
PMI Japan to Launch Limited Edition IQOS ILUMA i "Galaxy Blue", Introduces New TEREA Clear Regular Flavo
PMI Japan to Launch Limited Edition IQOS ILUMA i "Galaxy Blue", Introduces New TEREA Clear Regular Flavo
PMI Japan unveils limited edition IQOS ILUMA i in Galaxy Blue, inspired by the universe, set to launch on October 29.
Oct.14 by 2FIRSTS.ai
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai
Michigan Senator introduces bill to strengthen regulation of tobacco and nicotine products, amend tax law
Michigan Senator introduces bill to strengthen regulation of tobacco and nicotine products, amend tax law
The Michigan Senate in the United States proposed Bill No. 582, which aims to strengthen the regulation of tobacco and nicotine products, and violations will face penalties.
Sep.28 by 2FIRSTS.ai
PMI Q3 2025 Earnings: Net Revenues Reach $10.85 Billion, Smoke-Free Products Account for 41% of Sales
PMI Q3 2025 Earnings: Net Revenues Reach $10.85 Billion, Smoke-Free Products Account for 41% of Sales
PMI reported strong third-quarter 2025 results, underscoring the continued success of its smoke-free transformation. Net revenues rose 9.4% year-over-year to $10.85 billion, driven by robust growth in the smoke-free segment, which now accounts for 41% of total net revenues and over 42% of gross profit.Despite a 3.2% decline in cigarette shipments, combustible revenues climbed 4.3% thanks to strong pricing.
Oct.21